Literature DB >> 11568047

Factors related to pleural effusions after Fontan procedure in the era of fenestration.

R T Fedderly1, B N Whitstone, S J Frisbee, J S Tweddell, S B Litwin.   

Abstract

BACKGROUND: Significant pleural effusions after the Fontan operation prolong hospital stay, may increase the risk of infection, and may necessitate a pleurodesis procedure. METHODS AND
RESULTS: From February 1991 to April 2000, 98 consecutive patients under the age of 18 years underwent the fenestrated Fontan procedure at Children's Hospital of Wisconsin. Ninety-four patients who survived at least 30 days after surgery were retrospectively evaluated for the following factors: age, ventricular morphology (right single ventricle, left single ventricle [RV/LV]), fenestration open (FO) or closed (FC) at end of operation, intracardiac Fontan (IF) or extracardiac Fontan (EF), days with chest tube output per day >5, 10, and/or 20 mL. kg(-1). d(-1) (CTO5, CTO10, and CTO20, respectively), need for pleurodesis, length of hospital stay (LOS), operation during winter respiratory viral season of November through March (ReVS+, ReVS-), and pre-Fontan mean pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR). In univariate analysis, the ReVS+ patients had prolonged LOS, greater chest tube output, and more pleurodesis (P<0.05), and PAP was related to CTO5 and CTO10 but not to CTO20 or LOS. No significant differences were found in LOS, CTO5, CTO10, CTO20, and need for pleurodesis between patients in RV/LV, FO/FC, IF/EF, or PVR groups. Patients <4 years of age had more instances of CTO20 (P<0.05). When we used ordinary least squares regression analysis with age, FO or FC, RV or LV, PAP, and ReVS+ or ReVS- to predict each of CTO5, CTO10, CTO20, and LOS, only ReVS+ or ReVS- and age were statistically significant in all models.
CONCLUSIONS: Use of the Fontan procedure during the respiratory viral season appeared to be related to significant, prolonged pleural effusions and longer hospitalizations.

Entities:  

Mesh:

Year:  2001        PMID: 11568047     DOI: 10.1161/hc37t1.094817

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  15 in total

1.  Early Postoperative Albumin Administration Contributes to Morbidity After the Fontan Operation.

Authors:  Hayden J Zaccagni; Jeffrey A Alten; David C Cleveland; R Tyler Argent; Mark A Law; Ayesha S Bryant; Santiago Borasino
Journal:  Pediatr Cardiol       Date:  2016-06-09       Impact factor: 1.655

2.  Prophylactic Opening of the Pleural Cavity for Postoperative Drainage is a Risk Factor for Prolonged Pleural Effusion After a Fontan Operation.

Authors:  Naoki Masaki; Mizumoto Masahiro; Satoshi Matsuo; Sadahiro Sai
Journal:  Pediatr Cardiol       Date:  2019-08-29       Impact factor: 1.655

3.  Factors affecting Fontan length of stay: Results from the Single Ventricle Reconstruction trial.

Authors:  Chitra Ravishankar; Eric Gerstenberger; Lynn A Sleeper; Andrew M Atz; Jeremy T Affolter; Timothy J Bradley; J William Gaynor; Bryan H Goldstein; Heather T Henderson; Jeffrey P Jacobs; Alan B Lewis; Carolyn Dunbar-Masterson; Shaji C Menon; Victoria L Pemberton; Christopher J Petit; Nancy A Pike; Christian Pizarro; Kurt R Schumacher; Ismee A Williams; Jane W Newburger
Journal:  J Thorac Cardiovasc Surg       Date:  2015-09-28       Impact factor: 5.209

4.  Early pleural effusions related to the myocardial injury after open-heart surgery for congenital heart disease.

Authors:  Monesha Gupta-Malhotra; Jeffrey H Kern; Patrick A Flynn; Myles S Schiller; Jan M Quaegebeur; Deborah M Friedman
Journal:  Congenit Heart Dis       Date:  2010 May-Jun       Impact factor: 2.007

Review 5.  Hypoplastic left heart syndrome: current considerations and expectations.

Authors:  Jeffrey A Feinstein; D Woodrow Benson; Anne M Dubin; Meryl S Cohen; Dawn M Maxey; William T Mahle; Elfriede Pahl; Juan Villafañe; Ami B Bhatt; Lynn F Peng; Beth Ann Johnson; Alison L Marsden; Curt J Daniels; Nancy A Rudd; Christopher A Caldarone; Kathleen A Mussatto; David L Morales; D Dunbar Ivy; J William Gaynor; James S Tweddell; Barbara J Deal; Anke K Furck; Geoffrey L Rosenthal; Richard G Ohye; Nancy S Ghanayem; John P Cheatham; Wayne Tworetzky; Gerard R Martin
Journal:  J Am Coll Cardiol       Date:  2012-01-03       Impact factor: 24.094

6.  Risk Factors for Prolonged Pleural Effusion After Extracardiac Fontan Operation.

Authors:  Geena Kim; Hoon Ko; Joung-Hee Byun; Hyoung Doo Lee; Hyungtae Kim; Si Chan Sung; Kwang Ho Choi
Journal:  Pediatr Cardiol       Date:  2019-08-21       Impact factor: 1.655

7.  Center variation in patient age and weight at Fontan operation and impact on postoperative outcomes.

Authors:  Michelle C Wallace; James Jaggers; Jennifer S Li; Marshall L Jacobs; Jeffrey P Jacobs; Daniel K Benjamin; Sean M O'Brien; Eric D Peterson; P Brian Smith; Sara K Pasquali
Journal:  Ann Thorac Surg       Date:  2011-05       Impact factor: 4.330

8.  A prospective study of risk factors associated with persistent pleural effusion after total cavopulmonary connection with special reference to serum cortisol level.

Authors:  Sachin Talwar; Anupam Das; Rajesh Khadgawat; Manoj Kumar Sahu; Shiv Kumar Choudhary; Balram Airan
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2017-12-08

9.  Routine Sildenafil Does Not Improve Clinical Outcomes After Fontan Operation.

Authors:  J Leslie Gaddis Collins; Mark A Law; Santiago Borasino; W Clinton Erwin; David C Cleveland; Jeffrey A Alten
Journal:  Pediatr Cardiol       Date:  2017-09-07       Impact factor: 1.655

10.  Variation in care for children undergoing the Fontan operation for hypoplastic left heart syndrome.

Authors:  Aaron W Eckhauser; Maria I Van Rompay; Chitra Ravishankar; Jane W Newburger; S Ram Kumar; Christian Pizarro; Nancy Ghanayem; Felicia L Trachtenberg; Kristin M Burns; Garick D Hill; Andrew M Atz; Michelle S Hamstra; Mjaye Mazwi; Patsy Park; Marc E Richmond; Michael Wolf; Jeffrey D Zampi; Jeffrey P Jacobs; L LuAnn Minich
Journal:  Cardiol Young       Date:  2019-11-26       Impact factor: 1.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.